Intradigm

Company Executives

Powered by >>  Total Executives: 11

Company Overview

Intradigm is a private biotechnology company committed to the development of systematic RNA interference (RNAi) therapeutics for the treatment of serious diseases with an initial focus on oncology. The company's expertise in drug development and delivery serves as the foundation of Intradigm's RNAi platform. In particular, the company's novel and proprietary RNAi Nanoplex delivery technology is unique in its ability to enable the targeted delivery of RNAi therapeutics to specific tissues through systemic administration of the drug product. At present, Intradigm is working to build a high-value internal pipeline of RNAi oncology therapeutics and is actively advancing its lead drug candidate (ICS-283), a bimodal angiogenesis inhibitor, for a variety of cancer indications. Analysts currently estimate 2007 global oncology sales of greater than $50 billion1 with the leading anti-angiogenesis antibody drug earning annual sales in excess of $2 billion in the United States alone2.

content provided by Dow Jones & Co., Inc. and may be inaccurate

News from bizjournals

• Intradigm adds $2.9M, loses CEO (San Francisco -- 01.07.09)
• Intradigm closes final tranche of $21.4M round, names new CEO (San Jose -- 01.07.09)
• Intradigm raises $18.5 million (San Francisco -- 10.02.08)
• Intradigm raises $18.5M in 2nd round (San Jose -- 10.02.08)

• Help
• Advertise
• Site Map
• Archive
• Contact Portfolio
• Contributors
• Newsletters
• RSS